Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7451.085 | 0.9842 | 0.9852 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7451.085 | 0.9886 | 0.9893 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7451.085 | 0.3700 | 0.2584 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7451.085 | 0.0038 | -0.8510 | 2.1458 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7452.084 | 0.9429 | 0.9312 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7452.084 | 0.9349 | 0.9215 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7452.084 | 1.0177 | 1.0210 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7452.084 | 0.9893 | 0.9872 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7452.084 | 1.0616 | 1.0725 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7452.084 | 0.9882 | 0.9860 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7452.084 | 0.2878 | -0.0470 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7452.084 | 0.1346 | -0.3937 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7452.084 | 0.0136 | -0.8452 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7453.084 | 0.9302 | 0.9093 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7453.084 | 1.0022 | 1.0029 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7453.084 | 0.9770 | 0.9704 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7453.084 | 1.0105 | 1.0135 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7453.084 | 1.2197 | 1.2717 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7453.084 | 0.9857 | 0.9817 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7453.084 | 1.0784 | 1.0993 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7453.084 | 1.0006 | 1.0008 | 1.5592 | |
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7453.084 | 1.0319 | 1.0407 | 1.5592 | |
| HCC1954 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7456.084 | 0.9126 | 0.9098 | 1.9822 | |
| HCC1954 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7456.084 | 0.9694 | 0.9689 | 1.9822 | |
| HCC1954 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7456.084 | 0.9183 | 0.9158 | 1.9822 |